(MENAFN- GlobeNewsWire - Nasdaq) New York, May 05, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Somatostatin Analogs Industry" -
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Somatostatin Analogs Market to Reach $12.4 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Somatostatin Analogs estimated at US$7.3 Billion in the year 2022, is projected to reach a revised size of US$12.4 Billion by 2030, growing at aCAGR of 6.8% over the period 2022-2030. Octreotide, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Pasireotide segment is readjusted to a revised 8.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 10.9% CAGR
The Somatostatin Analogs market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 5.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.
Select Competitors (Total 43 Featured)
- Camurus AB
- Chiasma Inc.
- Crinetics Pharmaceuticals
- Dauntless Pharmaceuticals
- Ipsen Pharma
- Midatech Pharma PLC
- Novartis AG
- Peptron, Inc
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals Inc
Read the full report:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Somatostatin Analogs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Somatostatin Analogs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Somatostatin Analogs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Somatostatin Analogs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Octreotide by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Octreotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 6: World 16-Year Perspective for Octreotide by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Pasireotide by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Pasireotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Pasireotide by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Lanreotide by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Lanreotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 12: World 16-Year Perspective for Lanreotide by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Acromegaly by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Acromegaly by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 15: World 16-Year Perspective for Acromegaly by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for
Neuroendocrine Tumors (NETs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Neuroendocrine Tumors
(NETs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Neuroendocrine Tumors
(NETs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 19: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 21: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 22: World Somatostatin Analogs Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 23: USA Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 24: USA Historic Review for Somatostatin Analogs by Type -
Octreotide, Pasireotide and Lanreotide Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 25: USA 16-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 26: USA Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 27: USA Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 28: USA 16-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
CANADA
Table 29: Canada Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 30: Canada Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 31: Canada 16-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 32: Canada Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 33: Canada Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 34: Canada 16-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
JAPAN
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 35: Japan Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 36: Japan Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 37: Japan 16-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 38: Japan Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 39: Japan Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 40: Japan 16-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
CHINA
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 41: China Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 42: China Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 43: China 16-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 44: China Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 45: China Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 46: China 16-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
EUROPE
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 47: Europe Recent Past, Current & Future Analysis for
Somatostatin Analogs by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 48: Europe Historic Review for Somatostatin Analogs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 49: Europe 16-Year Perspective for Somatostatin Analogs
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
Table 50: Europe Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 51: Europe Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 52: Europe 16-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 53: Europe Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 54: Europe Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 55: Europe 16-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
FRANCE
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 56: France Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 57: France Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 58: France 16-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 59: France Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 60: France Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 61: France 16-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
GERMANY
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 62: Germany Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 63: Germany Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 64: Germany 16-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 65: Germany Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 66: Germany Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 67: Germany 16-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
ITALY
Table 68: Italy Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 69: Italy Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 70: Italy 16-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 71: Italy Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 72: Italy Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 73: Italy 16-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
UNITED KINGDOM
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 74: UK Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 75: UK Historic Review for Somatostatin Analogs by Type -
Octreotide, Pasireotide and Lanreotide Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 76: UK 16-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 77: UK Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 78: UK Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 79: UK 16-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
SPAIN
Table 80: Spain Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 81: Spain Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 82: Spain 16-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 83: Spain Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 84: Spain Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 85: Spain 16-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
RUSSIA
Table 86: Russia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 87: Russia Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 88: Russia 16-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 89: Russia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 90: Russia Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 91: Russia 16-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 93: Rest of Europe Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 94: Rest of Europe 16-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2014, 2023 &
2030
Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 96: Rest of Europe Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 97: Rest of Europe 16-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2014, 2023 & 2030
ASIA-PACIFIC
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Somatostatin Analogs by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 99: Asia-Pacific Historic Review for Somatostatin Analogs
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 100: Asia-Pacific 16-Year Perspective for Somatostatin
Analogs by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2014, 2023 & 2030
Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 102: Asia-Pacific Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 103: Asia-Pacific 16-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2014, 2023 &
2030
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 105: Asia-Pacific Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 106: Asia-Pacific 16-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2014, 2023 & 2030
AUSTRALIA
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Australia for 2023 (E)
Table 107: Australia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 108: Australia Historic Review for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 109: Australia 16-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2014, 2023 &
2030
Table 110: Australia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 111: Australia Historic Review for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 112: Australia 16-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2014, 2023 & 2030
INDIA
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in India for 2023 (E)
Table 113: India Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 114: India Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 115: India 16-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2014, 2023 & 2030
Table 116: India Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 117: India Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 118: India 16-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2014, 2023 & 2030
SOUTH KOREA
Table 119: South Korea Recent Past, Current & Future Analysis
for Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 120: South Korea Historic Review for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 121: South Korea 16-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2014, 2023 &
2030
Table 122: South Korea Recent Past, Current & Future Analysis
for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 123: South Korea Historic Review for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 124: South Korea 16-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2014, 2023 & 2030
REST OF ASIA-PACIFIC
Table 125: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Somatostatin Analogs by Type - Octreotide,
Pasireotide and Lanreotide - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 126: Rest of Asia-Pacific Historic Review for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 127: Rest of Asia-Pacific 16-Year Perspective for
Somatostatin Analogs by Type - Percentage Breakdown of Value
Sales for Octreotide, Pasireotide and Lanreotide for the Years
2014, 2023 & 2030
Table 128: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 129: Rest of Asia-Pacific Historic Review for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 130: Rest of Asia-Pacific 16-Year Perspective for
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report:
About reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
